Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics

Stoffel, Elina; Maier, Harald; Riedl, Elisabeth; Brüggen, Marie‐Charlotte; Reininger, Bärbel; Schaschinger, M; Bangert, Christine; Guenova, Emmanuella; Stingl, Georg; Brunner, Patrick M.

doi:10.1111/bjd.16126

Cited by 40 publications

(38 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, Stoffel et al . reported that EE induced by anti‐TNF‐α showed high levels of IL‐22, not only when compared with psoriasiform lesions that occurred with anti‐TNF‐α treatment, but also compared with conventional psoriasis and eczema lesions . Indeed, IL‐22 has been demonstrated to promote epidermal hyperplasia and to inhibit epidermal differentiation in spongiotic lesions .…”

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 99%

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

et al. 2019

View full text Add to dashboard Cite

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 99%

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

et al. 2019

View full text Add to dashboard Cite

“…Several studies demonstrated a clinically significant improvement for patients with AD underwent treatment with TNF‐α blockers . However, there is also a report mentioned anti‐TNF‐α–induced AD . Therefore, the precise mechanism of TNF‐α in the pathogenesis of AD is still plausible, which remains to be determined.…”

Section: Discussionmentioning

confidence: 99%

Toll‐like receptor 4 attenuates a murine model of atopic dermatitis through inhibition of langerin‐positive DCs migration

Lin

Xie

Chen

et al. 2018

Experimental Dermatology

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that is often associated with skin barrier dysfunction leading to a higher frequency of bacterial and viral skin infections. Toll-like receptor (TLR) 4 on resident skin cells was involved in sensing pathogens and eliciting pathogen-specific innate and adaptive immune responses. Previous studies have demonstrated that TLR4 was linked to AD severity in context of pathogen infection. However, the immune regulatory role of TLR4 in AD remains to be defined. We here investigated the immune regulatory function of TLR4 in AD induced by repeated epicutaneous application of a hapten, 2,4-dinitrochlorobenzene (DNCB). Our results showed that TLR4-deficient (TLR4 ) mice exhibited more severe AD symptoms than WT mice after DNCB challenge. The DNCB-treated TLR4 mice also displayed higher expression levels of inflammatory cytokines and stronger Th2 response than WT counterparts. Moreover, the skin expression of thymic stromal lymphopoietin (TSLP), an important potential contributor to allergic inflammation, was significantly elevated in TLR4 mice compared with that in WT mice upon DNCB administration. Furthermore, we demonstrated that the migration of langerin-positive dendritic cells (DCs) into draining lymph nodes was enhanced in TLR4 mice following DNCB challenge, which is partially dependent on the production of pro-inflammatory cytokine TNF-α. Together, these results determined that TLR4 affected the hapten-induced skin inflammation in the absence of exogenous pathogen infection, suggesting that TLR4 not only regulates infection but also may serve as a modulator of the immune response during AD development.

show abstract

“…Der Ausdruck "anti-TNF-α-induzierte(s) Psoriasis/Ekzem" wurde durch die zutreffendere Bezeichnung "psoriasis-/eczema-like drug-related skin eruption" ersetzt. In einer kleinen Studie konnte gezeigt werden, dass sich anti-TNF-α-induzierte Psoriasis-ähnliche Hautläsionen in wesentlichen molekularen und zellulären Charakteristika von genuiner Psoriasis sowie von Dermatitis/Ekzem unterscheiden [229]. Nachdem das klinische Bild medikamentös induzierter Psoriasis-ähnlicher Läsionen häufig unklar und schwer von einer Dermatitis bzw.…”

Section: Psoriasis-ähnliche Und Ekzem-ähnliche Anti-tnf-α-assoziierteunclassified

Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Miehsler¹,

Dejaco

Gröchenig³

et al. 2018

Z Gastroenterol

View full text Add to dashboard Cite

Anti-TNFα-antibodies have revolutionized the therapy of inflammatory bowel diseases and other immune-mediated inflammatory diseases. Due to the increasing application of these substances, the Working Group of Inflammatory Bowel Diseases of the Austrian Association of Gastroenterology and Hepatology intended to update their consensus report on the safe use of Infliximab (published in 2010) and to enlarge its scope to cover all anti-TNFα-antibodies. The present consensus report summarizes the current evidence on the safe use of anti-TNFα-antibodies and covers the following topics: general risk of infection, bacterial infections (i. e., Clostridium difficile, Tuberculosis, food hygiene), Pneumocystis jiroveci, viral infections (i. e., Hepatitis B, Hepatitis C, HIV, CMV, VZV), vaccination in general and recommendation for vaccines, gastrointestinal aspects (i. e., perianal fistula, abdominal fistula, intestinal strictures, stenosis and bowel obstruction), dermatologic aspects (skin malignancies, eczema-like drug-related skin eruption), infusion reactions and immunogenicity, demyelinating diseases, hepatotoxicity, haematotoxicity, congestive heart failure, risk and history of malignancies, and pregnancy and breast feeding. For practical reasons, the relevant aspects are summarized in a checklist which is divided into two parts: issues to be addressed before therapy and issues to be addressed during therapy.

show abstract

Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics

Abstract: New-onset anti-TNF-α-induced eruptions previously classified as psoriasis or spongiotic dermatitis (eczema) exhibit a molecular profile that is different from either of these disorders.

Cited by 40 publications

References 57 publications

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

Toll‐like receptor 4 attenuates a murine model of atopic dermatitis through inhibition of langerin‐positive DCs migration

Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Contact Info

Product

Resources

About